Blood tumor mutational burden (bTMB) from circulating tumor DNA (ctDNA) as a biomarker for both mutational status and tumor burden in non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Davis, Andrew A. [1 ]
Galvez, Carlos [1 ]
Pan, Alan [1 ]
Mohindra, Nisha [1 ]
Villaflor, Victoria [1 ]
Chae, Young Kwang [1 ]
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3644
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3644
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Variant Detection and Tumor Mutational Burden (TMB) Concordance in Blood and Tumor Tissue Using Next-Generation Sequencing (NGS) in Patients with Non-small Cell Lung Cancer (NSCLC)
    Baden, J.
    Chang, H.
    Greenawalt, D. M.
    Kirov, S.
    Pant, S.
    Seminara, A.
    Srinivasan, S.
    Green, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1170 - 1170
  • [42] Tumor mutational burden and efficacy of chemotherapy in lung cancer
    Juan Song
    Yu Yan
    Cuicui Chen
    Jiamin Li
    Ning Ding
    Nuo Xu
    Hairong Bao
    Xin Zhang
    Qunying Hong
    Jian Zhou
    Yang W. Shao
    Yuanlin Song
    Lin Tong
    Jie Hu
    Clinical and Translational Oncology, 2023, 25 : 173 - 184
  • [43] Lung Cancer with a High Tumor Mutational Burden REPLY
    Gandhi, Leena
    Garassino, Marina C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11):
  • [44] Tumor mutational burden and efficacy of chemotherapy in lung cancer
    Song, Juan
    Yan, Yu
    Chen, Cuicui
    Li, Jiamin
    Ding, Ning
    Xu, Nuo
    Bao, Hairong
    Zhang, Xin
    Hong, Qunying
    Zhou, Jian
    Shao, Yang W.
    Song, Yuanlin
    Tong, Lin
    Hu, Jie
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (01): : 173 - 184
  • [45] Prognostic Role of Circulating Tumor DNA (ctDNA) and Immune Cell Biomarkers in Non-Small Cell Lung Cancer (NSCLC)
    Chae, Y. K.
    Agte, S.
    Davis, A.
    Pan, A.
    Simon, N.
    Mohindra, N.
    Villaflor, V.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2242 - S2242
  • [46] Characterizing changes in tumor mutational burden (TMB) by serial circulating tumor DNA (ctDNA) testing in patients with advanced prostate cancer (aPC).
    Childs, Daniel S.
    Kwon, Eugene D.
    Ahmed, Mohamed E.
    Mahmoud, Ahmed
    Pessoa, Rodrigo Rodrigues
    Nabavizadeh, Reza
    Tsai, Jill
    Drusbosky, Leylah
    Bucheit, Leslie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [47] Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
    Yang, Jialiang
    Hui, Yan
    Zhang, Yanxiang
    Zhang, Minghui
    Ji, Binbin
    Tian, Geng
    Guo, Yangqiang
    Tang, Min
    Li, Lianxing
    Guo, Bella
    Ma, Tonghui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [48] The impact of genomic mutational status and correlation with tumor mutation burden in non-small cell lung cancer of Xuanwei, Yunnan Province, China
    Liu, Yinqiang
    Liang, Jin
    Zhao, Juan
    Zhang, Shuirong
    Zhang, Shiyue
    Shi, Yunfei
    Huang, Ruoshan
    Wang, Xiaojie
    CANCER RESEARCH, 2020, 80 (16)
  • [49] The impact of genomic mutational status on PD-L1 expression and tumor mutation burden in non-small cell lung cancer
    Zhou, Qing
    Gu, Weiguang
    Fu, WenFan
    Mai, Shijie
    Lin, Daren
    Zhang, Shiyue
    Wang, Wenjing
    Zhang, Peng
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer
    Lebow, E. S.
    Murciano-Goroff, Y.
    Razavi, P.
    Reis-Filho, J. S.
    Flynn, J.
    Zhang, Z.
    Tu, H. Y.
    Bertucci, C.
    Lim, L. P.
    Li, M.
    Drilon, A.
    Riely, G.
    Rudin, C. M.
    Jones, D.
    Yang, T. J.
    Rimner, A.
    Arcila, M. E.
    Isbell, J.
    Li, B. T.
    Gomez, D. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S174 - S174
12345